Research and Markets (http://www.researchandmarkets.com/research/rnql6x/hemorrhage) has announced the addition of the "Hemorrhage - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Hemorrhage, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhage and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Cellphire, Inc.
- Digna Biotech, S.L.
- Haemostatix Limited
- QRxPharma Limited
- Serendex Pharmaceuticals A/S
- Thrombotargets Europe SL
Drug Profiles
- DB-055
- eptacog alfa (activated)
- PeproStat
- Protein for Hematological Disorders, Dermatology, Shock and Injury
- Q-8008
- Small Molecule for Postpartum Hemorrhage
- Small Molecules to Block Kir 7.1 for Postpartum Hemorrhage
- Thrombosomes
- TT-111
- TT-112
- V-0801
For more information visit http://www.researchandmarkets.com/research/rnql6x/hemorrhage
View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005320/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Hematological
